Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Thalassemia 1Primary Myelofibrosis 1Polycythemia Vera 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Specimen Handling 3Cisplatin 3Magnetic Resonance Spectroscopy 2Letrozole 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1ruxolitinib 1rozanolixizumab 1pyrotinib 1pirtobrutinib 1olutasidenib 1obinutuzumab 1niraparib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1fluciclovine F-18 1enfortumab vedotin 1darolutamide 1dabrafenib 1cabozantinib 1apalutamide 1adacel 1acalabrutinib 1Watchful Waiting 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Panobinostat × 30 days × Clear all
NCT02386800 2026-05-27

CINC424A2X01B Rollover Protocol

Novartis

Phase 4 Active not recruiting
279 enrolled
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡